Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas

Full text
Author(s):
Coutinho-Camillo, Claudia Malheiros [1, 2] ; Lourenco, Silvia Vanessa [3] ; Nonogaki, Suely [1] ; Vartanian, Jose Guilherme [4] ; Nagai, Maria Aparecida [5] ; Kowalski, Luiz Paulo [4] ; Soares, Fernando Augusto [1, 3]
Total Authors: 7
Affiliation:
[1] AC Camargo Canc Ctr, Dept Anat Pathol, Sao Paulo - Brazil
[2] Ctr Int Pesquisa, AC Camargo Canc Ctr, BR-01508010 Sao Paulo - Brazil
[3] Univ Sao Paulo, Sch Dent, Dept Gen Pathol, Sao Paulo - Brazil
[4] Hosp AC Camargo Fund Antonio Prudente, Dept Otorhinolaryngol & Head & Neck Surg, Sao Paulo - Brazil
[5] Univ Sao Paulo, Sch Med, Dept Radiol & Oncol, Discipline Oncol, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Virchows Archiv; v. 463, n. 1, p. 31-39, JUL 2013.
Web of Science Citations: 9
Abstract

PAR-4 is a tumor suppressor protein with a pro-apoptotic function and down-regulation of PAR-4 is seen in a variety of tumors. PHLDA1 gene overexpression has been shown to reduce cell proliferation and induce cell death in a variety of cell types. In this study, 229 cases of oral squamous cell carcinoma (OSCC), arranged in a tissue microarray, were analyzed by immunohistochemistry. PAR-4 expression was predominantly moderate to strong and expression of PHLDA1 was predominantly negative or weak. Cytoplasmic expression of PAR-4 was associated with advanced clinical stage. Expression of PHLDA1 was associated with advanced clinical stage of the tumour. Five-year overall and disease-free survival rates differed significantly between cases that did and cases that did not express PHLDA1, and by multivariate analysis, expression of PHLDA1 and PAR-4 were independent prognostic factors in OSCC patients. Expression of PAR-4 and PHLDA1 is altered in OSCC and might be a valuable prognostic indicator for this disease. (AU)

FAPESP's process: 98/14335-2 - Antonio Prudente Cancer Research Center
Grantee:Fernando Augusto Soares
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 08/57887-9 - National Institute of Oncogenomics
Grantee:Luiz Paulo Kowalski
Support Opportunities: Research Projects - Thematic Grants